MHRA Tells Devicemakers to Balance Risk With Need to Show Efficacy

International Medical Device Regulatory Monitor
A A
Medtech sponsors should balance the need to demonstrate safety and efficacy with the potential risks to patients when determining the size and duration of a clinical trial, a new guidance by the UK’s Medicines and Healthcare products Regulatory Agency says.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $40.00